What is the “montelukast intermediate” market in China?
The phrase “China montelukast intermediate market” usually refers to the upstream chemicals used to manufacture montelukast (a leukotriene-receptor antagonist marketed globally, including as Singulair). In practice, this market covers the production and supply of key synthesis building blocks and intermediates that are later converted into montelukast API (active pharmaceutical ingredient), followed by eventual formulation into tablets/granules.
Which intermediates are typically traded?
Searches phrased this way often point to custom chemical synthesis and contract manufacturing (CMO/CDMO) for one or more montelukast synthesis intermediates. However, the specific intermediates (names/codes, purity grades, and supply chain steps) vary by supplier process route and by whether the buyer is targeting API production, scale-up, or route development.
If you share:
1) the intermediate name(s) you mean (or a CAS number), and
2) whether you want API-focused supply or fine-chemical trading,
I can narrow to the exact segment you’re after.
Who buys montelukast intermediates in China?
Common buyers include:
- API manufacturers that make montelukast in-house or through CMOs/CDMOs.
- Chemical trading houses that consolidate supply for downstream pharma producers.
- Contract synthesis providers building kilograms to metric-ton scale intermediates for API campaigns.
Demand tends to track montelukast API production schedules, which also respond to regulatory approvals, tenders, and formulation demand.
What drives pricing and supply?
For intermediate markets in China, the main pricing drivers are usually:
- Raw material costs and availability for the precursor steps.
- Yield and process efficiency (how much intermediate you get per batch).
- Regulatory and quality requirements (GMP expectations, impurity control, documentation).
- Shipment/lead times and batch scheduling (especially when campaigns are run seasonally or tied to API demand).
Because intermediate specifications can differ by supplier (impurity profiles, residual solvents, particle size impacts for downstream), price comparisons often depend on matching the same grade and intended use.
Is montelukast still subject to patent/exclusivity constraints?
For market sizing or investment decisions, companies often check patent and exclusivity status for montelukast and related manufacturing processes, because it affects API competition and downstream purchasing patterns.
If you’re looking specifically for patent/exclusivity research on montelukast (including China-relevant claims), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ [1]
What regulations matter for chemical intermediates?
Intermediate supplies are generally constrained by:
- GMP/DMF-style documentation requirements downstream (even if the intermediate itself is not always marketed as a finished drug).
- Environmental compliance for chemical synthesis steps (waste handling, emissions).
- Traceability and impurity limits that affect final API approval and batch release.
These rules tend to favor suppliers with stable documentation and consistent impurity control, which can tighten supply and raise cost during compliance upgrades.
---
Quick next step (so the answer matches what you want)
When you say “China montelukast intermediate market,” do you mean:
1) market size/supply overview for montelukast synthesis intermediates, or
2) a specific intermediate chemical (name/CAS), or
3) buying/sourcing (suppliers, price ranges, MOQ, lead times)?
Reply with the intermediate name or CAS number and your goal (research vs sourcing), and I’ll tailor the market view to the correct segment.
Sources
[1] https://www.drugpatentwatch.com/